Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society for Medical Oncology (ESMO)
ESMO 2016
ESMO 2016
Phase 2 Trial Data on Metformin Do Not Support Further Investigation as a Breast Cancer Therapy
ESMO 2016
Read More ›
Comparison of Sequential and Concomitant Adjuvant Trastuzumab Treatment in HER2+ Breast Cancer
ESMO 2016
The French SIGNAL and PHARE projects have collected data on more than 9800 patients with breast cancer since 2006. In evaluating the outcomes of sequential and concomitant administration of trastuzumab within this cohort, this study provides insight into the ideal administration protocol for patients with human epidermal growth factor receptor 2–positive (HER2+) breast cancer.
Read More ›
Outcome Disparities by Prognostic Indicators in HR+ Breast Cancer
ESMO 2016
The 21-gene Recurrence Score® is the result of a commercial genomic test that evaluates the likelihood that breast cancer will recur, and the likely benefit from chemotherapy and/or radiation therapy. This study evaluates disparities in hormone receptor–positive (HR+) breast cancer outcome by age and 21-gene Recurrence Score®.
Read More ›
Prognostic Role for Derived Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer
ESMO 2016
Previous studies have reported that an elevated neutrophil-to-lymphocyte ratio is associated with an increased risk of relapse and worse survival in women with breast cancer. Additional data about the prognostic role for this biomarker in patients with early breast cancer are presented here.
Read More ›
Interim Phase 2 Results on Abemaciclib in Women with HR+/HER2– Breast Cancer
ESMO 2016
In this ongoing phase 2 study, postmenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer are being treated with abemaciclib (a selective inhibitor of cyclin-dependent kinases 4 and 6), anastrozole (an aromatase inhibitor), or both simultaneously.
Read More ›
The FALCON Study: A Phase 3 Comparison of Fulvestrant and Anastrozole in ER+ Advanced Breast Cancer
ESMO 2016
Read More ›
Tumor Biomarker Analysis from the Phase 3 PALOMA-2 Trial
ESMO 2016
This study is designed to compare treatment with palbociclib (a cyclin-dependent kinase 4/6 inhibitor) in combination with letrozole (an aromatase inhibitor) versus placebo with letrozole in postmenopausal women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer. A secondary outcome measure of the study, the analysis of tumor tissue biomarkers, is presented here.
Read More ›
Antitumor Activity of PM01183 in BRCA-Associated Metastatic Breast Cancer
ESMO 2016
PM01183 (lurbinectedin) is an investigational compound that blocks transactivated transcription and induces the formation of double-strand breaks in a range of cancer lines. This study is designed to evaluate whether the presence of
BRCA1/2
mutations can act as a prognostic indicator of response to PM01183 in patients with metastatic breast cancer.
Read More ›
First-Line Everolimus plus Letrozole in ER+/HER– Breast Cancer
ESMO 2016
The objective of this study is to evaluate the efficacy and safety of everolimus (an inhibitor of mammalian target of rapamycin) in combination with letrozole (an aromatase inhibitor) in postmenopausal women with advanced estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer.
Read More ›
Preoperative Metabolic Profiles Are Prognostic for Breast Cancer Recurrence
ESMO 2016
Read More ›
Page 1 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us